255 related articles for article (PubMed ID: 29432385)
1. Economic Evaluation of Selective Neonatal Bacillus Calmette-Guérin Vaccination of High-risk Infants in Ireland.
Teljeur C; Moran PS; Harrington P; Butler K; Corcoran B; O'Donnell J; Usher C; O'Flanagan D; Connolly K; Ryan M
Pediatr Infect Dis J; 2018 Aug; 37(8):759-767. PubMed ID: 29432385
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of universal BCG vaccination of Japanese infants.
Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
[TBL] [Abstract][Full Text] [Related]
5. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
6. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.
Mangtani P; Nguipdop-Djomo P; Keogh RH; Trinder L; Smith PG; Fine PE; Sterne J; Abubakar I; Vynnycky E; Watson J; Elliman D; Lipman M; Rodrigues LC
Health Technol Assess; 2017 Jul; 21(39):1-54. PubMed ID: 28738015
[TBL] [Abstract][Full Text] [Related]
7. Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland.
Sweeney E; Dahly D; Seddiq N; Corcoran G; Horgan M; Sadlier C
BMC Infect Dis; 2019 May; 19(1):397. PubMed ID: 31072396
[TBL] [Abstract][Full Text] [Related]
8. Health economic evaluation of current vaccination strategies and new vaccines against tuberculosis: a systematic review.
Machlaurin A; Pol SV; Setiawan D; van der Werf TS; Postma MJ
Expert Rev Vaccines; 2019 Sep; 18(9):897-911. PubMed ID: 31369299
[No Abstract] [Full Text] [Related]
9. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment.
Altes HK; Dijkstra F; Lugnèr A; Cobelens F; Wallinga J
Epidemiology; 2009 Jul; 20(4):562-8. PubMed ID: 19295437
[TBL] [Abstract][Full Text] [Related]
10. Is Bacillus Calmette-Guerin revaccination necessary for Japanese children?
Rahman M; Sekimoto M; Hira K; Koyama H; Imanaka Y; Fukui T
Prev Med; 2002 Jul; 35(1):70-7. PubMed ID: 12079443
[TBL] [Abstract][Full Text] [Related]
11. Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
Jackson S; Kabir Z; Comiskey C
Vaccine; 2024 Mar; 42(8):2099-2105. PubMed ID: 38423810
[TBL] [Abstract][Full Text] [Related]
12. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.
MMWR Recomm Rep; 1996 Apr; 45(RR-4):1-18. PubMed ID: 8602127
[TBL] [Abstract][Full Text] [Related]
13. A review of the literature on the economics of vaccination against TB.
Tu HA; Vu HD; Rozenbaum MH; Woerdenbag HJ; Postma MJ
Expert Rev Vaccines; 2012 Mar; 11(3):303-17. PubMed ID: 22380823
[TBL] [Abstract][Full Text] [Related]
14. The benefits and risks of bacille Calmette-Guérin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model.
Clark M; Cameron DW
BMC Pediatr; 2006 Mar; 6():5. PubMed ID: 16515694
[TBL] [Abstract][Full Text] [Related]
15. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
Dye C
J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the neonatal BCG vaccination programme in Ireland.
Usher C; Adams R; Schmitz S; Kieran J; O'Flanagan D; O'Donnell J; Connolly K; Corcoran B; Butler K; Barry M; Walsh C
Arch Public Health; 2016; 74():28. PubMed ID: 27413531
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic impact of a specific BCG vaccination program implemented in Prato, central Italy, involving foreign newborns on hospitalizations.
Bellini I; Nastasi A; Boccalini S
Hum Vaccin Immunother; 2016 Sep; 12(9):2383-90. PubMed ID: 27184892
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis.
Abubakar I; Pimpin L; Ariti C; Beynon R; Mangtani P; Sterne JA; Fine PE; Smith PG; Lipman M; Elliman D; Watson JM; Drumright LN; Whiting PF; Vynnycky E; Rodrigues LC
Health Technol Assess; 2013 Sep; 17(37):1-372, v-vi. PubMed ID: 24021245
[TBL] [Abstract][Full Text] [Related]
19. Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan.
Favorov M; Ali M; Tursunbayeva A; Aitmagambetova I; Kilgore P; Ismailov S; Chorba T
PLoS One; 2012; 7(3):e32567. PubMed ID: 22427854
[TBL] [Abstract][Full Text] [Related]
20. Selective or universal neonatal BCG immunization: what policy for a district with a high incidence of tuberculosis?
Pharoah PD; Watson JM; Sen S
Public Health; 1996 May; 110(3):179-83. PubMed ID: 8668765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
